Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative drugs work by mimicking the natural actions of GLP-1, a hormone released by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these compounds increase insulin production and inhibit glucagon

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting considerable weight loss – they exhibit intriguing differences in th